Approach to the Management of Thyroid Eye Disease

Sabrina Yu; Vivian T. Yin

doi:10.58931/cdet.2023.1316

Authors

Sabrina Yu, MD Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia
Vivian T. Yin, MD, MPH Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia

DOI:

https://doi.org/10.58931/cdet.2023.1316

Abstract

Thyroid Eye Disease (TED), also known as Grave’s orbitopathy, is an autoimmune condition characterized by inflammation of the extraocular muscles, orbital fat and periocular tissues. As the most common orbital disease worldwide, its prevalence is estimated to be between 0.5–2% and it disproportionately affects females 4:1. Although the majority of TED cases occur in patients with Graves’ disease (80–90%), it can also be seen with patients with Hashimoto’s thyroiditis (10%), euthyroid individuals (5–10%) and thyroid cancer. At the time of initial Graves’ disease diagnosis, 25% of patients have clinically detectable orbital involvement that is often mild. The natural history of TED typically consists of an initial active inflammatory period lasting 6–36 months, which then plateaus and is followed by a quiescent fibrotic phase with stabilization of disease.

Author Biographies

Sabrina Yu, MD, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia

Dr. Sabrina Yu is a second-year resident in Ophthalmology at the University of British Columbia. She completed her undergraduate studies at the University of Calgary and her medical school training at the University of British Columbia.

Vivian T. Yin, MD, MPH, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia

Dr. Vivian T. Yin is a clinical associate professor at the University of British Columbia specialized in ophthalmic plastic and reconstructive surgery. She worked at Memorial Sloan Kettering Cancer Center in New York and returned to Vancouver in Nov 2019. She focuses on the treatment of periocular and orbital cancer, with the use of genetic-based targeted therapy and surgical innovations as her research interest, and speaks internationally on these topics. After completing her medical degree and ophthalmology residency at the University of Toronto, she pursued a prestigious 2-year fellowship training in Ophthalmic Plastics and Reconstructive Surgery at the University of Texas M.D. Anderson Cancer Center in Houston, Texas.

Dr. Yin also practices in global health with a Master in Public Health from the Johns Hopkins Bloomberg School of Public Health. She generously donates her spare time to work towards eliminating preventable blindness. She has traveled to Bangladesh, the Philippines, Nepal, Tunisia and India to teach and provide surgical care for those in need. She is the current chair of the Canadian Association for Public Health and Global Ophthalmology and the COS representative to the International Council of Ophthalmology. She was chair and member of the board of director for Seva Canada for 6 years.

References

Szelog J, Swanson H, Sniegowski MC, et al. Thyroid eye disease. Mo Med. 2022;119(4):343-350.

Dolman PJ. Grading severity and activity in thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018 Jul;34(4S):S34-40. DOI: https://doi.org/10.1097/IOP.0000000000001150

Bahn RS. Graves’ Ophthalmopathy. N Engl J Med. 2010 Feb 25;362(8):726-738. DOI: https://doi.org/10.1056/NEJMra0905750

Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest. 2014 Aug;37(8):691-700. DOI: https://doi.org/10.1007/s40618-014-0097-2

Menconi F, Profilo MA, Leo M, et al. Spontaneous improvement of untreated mild Graves’ ophthalmopathy: Rundle’s curve revisited. Thyroid. 2014 Jan;24(1):60-66. DOI: https://doi.org/10.1089/thy.2013.0240

Gaddipati RV, Meyer DR. Eyelid retraction, lid lag, lagophthalmos, and von Graefe’s sign. Ophthalmology. 2008 Jun;115(6):1083-1088. DOI: https://doi.org/10.1016/j.ophtha.2007.07.027

Bartley GB, Gorman CA. Diagnostic criteria for Graves’ ophthalmopathy. Am J Ophthalmol. 1995 Jun;119(6):792-5. DOI: https://doi.org/10.1016/S0002-9394(14)72787-4

McKeag D, Lane C, Lazarus JH, et al. Clinical features of dysthyroid optic neuropathy: a European group on Graves’ orbitopathy (EUGOGO) survey. Br J Ophthalmol. 2007 Apr 1;91(4):455–8. DOI: https://doi.org/10.1136/bjo.2006.094607

Burch HB, Perros P, Bednarczuk T, et al. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J. 2022 Dec 1;11(6):e220189. DOI: https://doi.org/10.1530/ETJ-22-0189

Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5(1):9-26. DOI: https://doi.org/10.1159/000443828

Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol.1996 Oct;45(4):477-481. DOI: https://doi.org/10.1046/j.1365-2265.1996.8220832.x

Träisk F, Tallstedt L, Abraham-Nordling M, et al. Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or idine-131. J Clin Endocrin Metab. 2009 Oct 1;94(10):3700-3707. DOI: https://doi.org/10.1210/jc.2009-0747

Marcocci C, Kahaly GJ, Krassas GE,, et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011 May 19;364(20):1920-2031. DOI: https://doi.org/10.1056/NEJMoa1012985

Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005 Sep;90(9):5234-5240. DOI: https://doi.org/10.1210/jc.2005-0148

Bartalena L, Krassas GE, Wiersinga W, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012 Dec 1;97(12):4454-4463. DOI: https://doi.org/10.1210/jc.2012-2389

Ebner R. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol. 2004 Nov 1;88(11):1380-1386. DOI: https://doi.org/10.1136/bjo.2004.046193

Xu DD, Chen Y, Xu HY. Long-term effect of triamcinolone acetonide in the treatment of upper lid retraction with thyroid associated ophthalmopathy. Int J Ophthalmol 2018 Aug 18;11(8):1290-1295.

Dolman PJ, Wirth MA. Glucocorticoids for thyroid eye disease. Int Ophthalmol Clin. 2021;61(2):63-78. DOI: https://doi.org/10.1097/IIO.0000000000000357

Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for Graves ophthalmopathy. Ophthalmology. 2008 Feb;115(2):398-409. DOI: https://doi.org/10.1016/j.ophtha.2007.10.028

Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, et al. Treatment modalities for Graves’ ophthalmopathy: systematic review and metaanalysis. J Clin Endocrin Metab. 2009 Aug 1;94(8):2708-2816. DOI: https://doi.org/10.1210/jc.2009-0376

Dolman PJ, Rath S. Orbital radiotherapy for thyroid eye disease: Curr Opin Ophthalmol. 2012 Sep;23(5):427-32. DOI: https://doi.org/10.1097/ICU.0b013e3283560b2b

Kahaly GJ, Rösler HP, Pitz S, et al. Low-versus high-dose radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial. J Clin Endocrin Metab. 2000 Jan 1;85(1):102-108. DOI: https://doi.org/10.1210/jcem.85.1.6257

Smith TJ, Kahaly GJ, Ezra DG, Fleming, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017 May 4;376(18):1748-1761. DOI: https://doi.org/10.1056/NEJMoa1614949

Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021 Jun;9(6):360-372. DOI: https://doi.org/10.1016/S2213-8587(21)00056-5

Ugradar S, Shi L, Wang Y, et al. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye. 2021 Sep;35(9):2607-2612. DOI: https://doi.org/10.1038/s41433-020-01297-w

Sears CM, Wang Y, Bailey LA, et al. Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study. Am J Ophthalmol Case Rep. 2021 Sep;23:101111. DOI: https://doi.org/10.1016/j.ajoc.2021.101111

Smith T. Evaluation of United States thyroid eye disease patients receiving an additional course of teprotumumab treatment over 2 years. Thyroid. 2022 Oct 1;32(S1):P-1-A-135.

Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment. Ophthalmol. 2022 Apr;129(4):438-449. DOI: https://doi.org/10.1016/j.ophtha.2021.10.017

Pérez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018 Nov;195:181-190. DOI: https://doi.org/10.1016/j.ajo.2018.07.038

Pérez-Moreiras JV, Varela-Agra M, Prada-Sánchez MC, et al. Steroid-resistant Graves’ orbitopathy treated with tocilizumab in real-world clinical practice: a 9-year single-center experience. J Clin Med. 2021 Feb 11;10(4):706. DOI: https://doi.org/10.3390/jcm10040706

Approach to the Management of Thyroid Eye Disease

Authors

DOI:

Abstract

Author Biographies

Sabrina Yu, MD, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia

Vivian T. Yin, MD, MPH, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia

References

Downloads

Published

How to Cite

Issue

Section

License

Summary

Open Access

License